Posted on Tuesday, May 18th, 2010 at 2:32 pm.
Opexa Therapeutics, a company that is developing Tovaxin, a T-cell therapy for multiple sclerosis, reported its financial results for the first quarter.
The report showed that the company will have sufficient capital through 2010. They also reported that the company will present data at the American Academy of Nuerology conference to show that they have indicated a link between Tovaxin’s action and the outcome in MS patients.
Research developments for the first quarter $783,534 for the three months before March 31, 2010, which is more than the year before. The increase in expense was mainly related to the increase in personnel.
If you are looking for help with your accounting needs, contact Austin corporate accounting today.